FDA Approves New, Larger Toujeo Pen

New pen can potentially reduce the number of injections and lower copay costs

The FDA has approved Toujeo (insulin glargine 300 units/mL, Sanofi) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market. The new pen holds 900 units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 units/mL of Toujeo in a single injection.

Due to its higher capacity, Max SoloStar may reduce the number of pens adults prescribed Toujeo use, allowing for fewer refills and related copays, depending on the person’s insurance coverage. The maximum dose of up to 160 units/mL may also help reduce the number of injections needed to deliver the required Toujeo dosage for some adults with diabetes.

Toujeo Max SoloStar will be available at the same price as the original Toujeo SoloStar per insulin unit. The new pen will launch in retail pharmacies across the U.S. in the third quarter of 2018.

Source: Sanofi; March 27, 2018.